Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 3.5% - Should You Sell?

Key Points

• Tiziana Life Sciences' stock price has decreased by 3.5%, trading at around $1.95 after falling from a previous close of $2.02.
• Weiss Ratings has reaffirmed a "sell (d-)" rating for Tiziana Life Sciences, with the consensus among analysts indicating a general sentiment of selling the stock.
• Institutional investors have shown significant activity, with Dauntless Investment Group purchasing approximately $1.88 million in shares and Jane Street Group increasing its stake by 968.2%.

Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report)'s stock price fell 3.5% during mid-day trading on Friday . The stock traded as low as $1.86 and last traded at $1.95. 382,024 shares traded hands during mid-day trading, a decline of 11% from the average session volume of 428,661 shares. The stock had previously closed at $2.02.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tiziana Life Sciences in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Sell".

Tiziana Life Sciences Stock Down 3.5%

The firm has a 50 day moving average price of $1.93 and a 200 day moving average price of $1.63.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Dauntless Investment Group LLC purchased a new position in shares of Tiziana Life Sciences during the 1st quarter valued at about $1,879,000. Jane Street Group LLC raised its stake in Tiziana Life Sciences by 968.2% during the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock worth $181,000 after acquiring an additional 151,858 shares during the period. OMERS ADMINISTRATION Corp purchased a new position in Tiziana Life Sciences during the first quarter valued at approximately $156,000. Bison Wealth LLC bought a new position in shares of Tiziana Life Sciences in the fourth quarter worth approximately $30,000. Finally, ARS Investment Partners LLC purchased a new stake in shares of Tiziana Life Sciences in the third quarter worth $66,000.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.